[go: up one dir, main page]

NO971997D0 - Bruk av immunmodulerende midler - Google Patents

Bruk av immunmodulerende midler

Info

Publication number
NO971997D0
NO971997D0 NO971997A NO971997A NO971997D0 NO 971997 D0 NO971997 D0 NO 971997D0 NO 971997 A NO971997 A NO 971997A NO 971997 A NO971997 A NO 971997A NO 971997 D0 NO971997 D0 NO 971997D0
Authority
NO
Norway
Prior art keywords
immunomodulatory agents
pka
well
pharmaceutical compositions
protein kinase
Prior art date
Application number
NO971997A
Other languages
English (en)
Inventor
Kjetil Tasken
Einar Martin Aandahl
Paal Aukrust
Bjoern S Skaalhegg
Fredrik Mueller
Stig Froeland
Vidar Hansson
Original Assignee
Kjetil Tasken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kjetil Tasken filed Critical Kjetil Tasken
Priority to NO971997A priority Critical patent/NO971997D0/no
Publication of NO971997D0 publication Critical patent/NO971997D0/no
Priority to ES98917808T priority patent/ES2171018T3/es
Priority to NZ501181A priority patent/NZ501181A/en
Priority to AT98917808T priority patent/ATE213944T1/de
Priority to PCT/NO1998/000134 priority patent/WO1998048809A1/en
Priority to JP54685698A priority patent/JP2002501499A/ja
Priority to DE69804125T priority patent/DE69804125T2/de
Priority to AU70865/98A priority patent/AU738674B2/en
Priority to EP98917808A priority patent/EP1024809B1/en
Priority to CA002288215A priority patent/CA2288215C/en
Priority to DK98917808T priority patent/DK1024809T3/da
Priority to PT98917808T priority patent/PT1024809E/pt
Priority to NO19995269A priority patent/NO325209B1/no
Priority to US11/136,560 priority patent/US20050250727A1/en
Priority to JP2009295046A priority patent/JP2010111688A/ja

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/12Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121Hammerhead

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
NO971997A 1997-04-29 1997-04-29 Bruk av immunmodulerende midler NO971997D0 (no)

Priority Applications (15)

Application Number Priority Date Filing Date Title
NO971997A NO971997D0 (no) 1997-04-29 1997-04-29 Bruk av immunmodulerende midler
PT98917808T PT1024809E (pt) 1997-04-29 1998-04-29 Utilizacao de agentes de imunomodulacao
DE69804125T DE69804125T2 (de) 1997-04-29 1998-04-29 Verwendung von immunomodulatoren
EP98917808A EP1024809B1 (en) 1997-04-29 1998-04-29 Use of immunomodulating agents
AT98917808T ATE213944T1 (de) 1997-04-29 1998-04-29 Verwendung von immunomodulatoren
PCT/NO1998/000134 WO1998048809A1 (en) 1997-04-29 1998-04-29 Use of immunomodulating agents
JP54685698A JP2002501499A (ja) 1997-04-29 1998-04-29 免疫調節剤の用途
ES98917808T ES2171018T3 (es) 1997-04-29 1998-04-29 Uso de agentes inmunomoduladores.
AU70865/98A AU738674B2 (en) 1997-04-29 1998-04-29 Use of immunomodulating agents
NZ501181A NZ501181A (en) 1997-04-29 1998-04-29 Use of inhibitors selected from cAMP antagonists, hammerhead ribozymes, sequence specific antisense oligonucleotides and anchoring disruption peptides for treating immunosuppressive diseases
CA002288215A CA2288215C (en) 1997-04-29 1998-04-29 Use of immunomodulating agents
DK98917808T DK1024809T3 (da) 1997-04-29 1998-04-29 Anvendelse af immunomodulatorer
NO19995269A NO325209B1 (no) 1997-04-29 1999-10-28 Anvendelse av immunmodulerende midler, peptid, hammerhoderibozymer, antisensoligonukleotider, farmasoytiske blandinger og inhibitorer.
US11/136,560 US20050250727A1 (en) 1997-04-29 2005-05-25 Use of immunomodulating agents
JP2009295046A JP2010111688A (ja) 1997-04-29 2009-12-25 免疫調節剤の用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO971997A NO971997D0 (no) 1997-04-29 1997-04-29 Bruk av immunmodulerende midler

Publications (1)

Publication Number Publication Date
NO971997D0 true NO971997D0 (no) 1997-04-29

Family

ID=19900676

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971997A NO971997D0 (no) 1997-04-29 1997-04-29 Bruk av immunmodulerende midler

Country Status (13)

Country Link
US (1) US20050250727A1 (no)
EP (1) EP1024809B1 (no)
JP (2) JP2002501499A (no)
AT (1) ATE213944T1 (no)
AU (1) AU738674B2 (no)
CA (1) CA2288215C (no)
DE (1) DE69804125T2 (no)
DK (1) DK1024809T3 (no)
ES (1) ES2171018T3 (no)
NO (1) NO971997D0 (no)
NZ (1) NZ501181A (no)
PT (1) PT1024809E (no)
WO (1) WO1998048809A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062315A2 (en) * 1998-05-27 1999-12-02 Lauras As Method for altering the activity of proteins of the pka signaling pathway
ATE322681T1 (de) * 1999-01-21 2006-04-15 Metamorphix Inc Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
WO2001042470A1 (en) * 1999-12-07 2001-06-14 University Of Medicine And Dentistry Of New Jersey Nucleic acid and protein expressed thereby and their involvement in stress
US6958214B2 (en) * 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
AU2003228809A1 (en) 2002-05-03 2003-11-17 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
WO2005060996A2 (en) * 2003-12-23 2005-07-07 Lauras As Method of altering the pka type i signalling pathway
GB0413726D0 (en) 2004-06-18 2004-07-21 Lauras As Compounds
GB0421355D0 (en) * 2004-09-24 2004-10-27 Univ Oslo Inhibitors
GB0518027D0 (en) * 2005-09-05 2005-10-12 Birkeland Innovasjon As Compounds
GB0618235D0 (en) * 2006-09-15 2006-10-25 Lauras As Process
CN105473134B (zh) 2013-06-05 2021-04-27 再生疗法有限公司 用于哺乳动物物种中诱导性组织再生的组合物和方法
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) * 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
US20230285556A1 (en) * 2021-09-13 2023-09-14 Omeros Corporation Methods and compositions for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568676A (en) * 1983-11-25 1986-02-04 Thomas Jefferson University Method of inhibiting aggregation using thromboxane synthetase inhibitor in combination with a cyclic AMP phosphodiesterase inhibitor
US5276017A (en) * 1990-09-14 1994-01-04 Trustees Of The University Of Pennsylvania Therapeutic and diagnostic applications of tropho-uteronectin (TUN) manipulation
US6429208B1 (en) * 1992-03-27 2002-08-06 Regents Of The University Of California Methods and compositions for restoring impaired cellular immune function
AU4226693A (en) * 1992-05-01 1993-11-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Phosphorothioate derivatives of cyclic AMP analogues
ATE312188T1 (de) * 1993-01-22 2005-12-15 Univ Research Corp Lokalisierung von therapeutischen mitteln
US5807693A (en) * 1994-11-23 1998-09-15 Icos Corporation Calcineurin inhibitory compounds and anchoring protein
US5795735A (en) * 1995-07-17 1998-08-18 Icos Corporation Isolated polynucleotides encoding PKA-binding proteins and methods of producing the proteins recombinantly
US5969117A (en) * 1995-08-17 1999-10-19 Hybridon, Inc. Modified protein kinase a-specific oligonucleotide

Also Published As

Publication number Publication date
WO1998048809A1 (en) 1998-11-05
PT1024809E (pt) 2002-07-31
EP1024809A1 (en) 2000-08-09
CA2288215A1 (en) 1998-11-05
ATE213944T1 (de) 2002-03-15
CA2288215C (en) 2009-08-18
AU738674B2 (en) 2001-09-20
DE69804125T2 (de) 2002-10-31
US20050250727A1 (en) 2005-11-10
DE69804125D1 (de) 2002-04-11
JP2010111688A (ja) 2010-05-20
AU7086598A (en) 1998-11-24
ES2171018T3 (es) 2002-08-16
EP1024809B1 (en) 2002-03-06
JP2002501499A (ja) 2002-01-15
DK1024809T3 (da) 2002-06-24
NZ501181A (en) 2002-03-01

Similar Documents

Publication Publication Date Title
ZA981627B (en) Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
DZ3191A1 (fr) Composés d'indazole et compositions pharmaceutiques inhibant les protéines kinases, et procédés d'utilisation de ceux-ci.
ATE215954T1 (de) Pyrazolo(4,3-d)pyrimidin-derivate und diese enthaltende pharmazeutische zubereitungen
CA2137203A1 (en) Protein kinase c inhibitors
FR2696094B1 (fr) Nouvelles compositions pharmaceutiques contenant des cyclosporines.
EA200200571A1 (ru) Новая композиция и ее применение
HUP0103617A2 (hu) Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
EA199900373A2 (ru) Фармацевтические композиции
CO5210911A1 (es) Trifluorbutenos nematicidas
DK1140993T3 (da) Glycopeptidderivater og farmaceutiske præparater indeholdende dem
NO973479L (no) Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme
DK0747050T4 (da) Farmaceutiske sammensætninger, der indeholder irbesartan
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
RS50485B (sr) Terapeutske kombinacije koje sadrže amplodipin i atorvastatin
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
NO971997D0 (no) Bruk av immunmodulerende midler
SE9604348D0 (sv) Användning av hydroxyguanidiner
SE9802937D0 (sv) Novel compounds
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
GEP20084346B (en) Protein kinase c inhibitors
HK1044145A1 (zh) N-(2-苯基-4-氨基丁基)-1-萘甲酰胺作為神經激肽-1受體拮抗劑
DK0838469T3 (da) 10,13,15-trioxatricyclo(9.2.1 9.6)-pentadecanon-derivater, fremgangsmåde til deres fremstilling og lægemidler indeholdende disse forbindelser
BR9605046B1 (pt) compostos n-(pirimidinl)-benzenossulfonamida e preparação farmacêutica contendo as mesmas.
TR199800152T1 (xx) Endotelin Resept�r Antagonistleri
FI923751A0 (fi) Hexahydrobenso/f/kinolinoner.